Spiegel Online manager-magazin.de

Mittwoch, 16. Oktober 2019

Börse

BUSINESS WIRE: Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

20.09.2019, 14:00 Uhr

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

  • Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement
  • The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics' intravitreal drug delivery technology
  • Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization

INGELHEIM, Germany and NEWTON, Mass. --(BUSINESS WIRE)-- 20.09.2019 --

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome's unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim's compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome's technology to deliver therapeutics in a biodegradable gel formulation into the eye.

"We are delighted to enter into a collaboration with a company of Boehringer Ingelheim's stature," said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. "We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development."

"Boehringer Ingelheim is looking forward to developing Inflammasome's novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome's highly experienced scientific team," said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. "This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options."

Anzeige

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome's novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

Please click on the link for ´Notes to Editors´and ´References´:

http://www.boehringer-ingelheim.com/press-release/collaboration-novel-therapies-retinal-diseases

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Inflammasome Therapeutics
Bev. Jedynak
Bevlyn Consulting
+1 312 943 1123
+1 773 350 5793
blj@bevylnconsulting.com

Weitere Nachrichten

21:22 BUSINESS WIRE: Die Leistungen von Dr. Steven Rosenberg bei der Krebsimmuntherapie inspirieren junge Forscher in Japan; Sieg beim XIV. Fujio Cup-Quiz zu Stammzellen geht an Indien.
21:14 BUSINESS WIRE: Mavenir bringt vollständig virtualisierte 4G/5G OpenRAN-Lösung auf den Markt
19:08 IRW-PRESS: Aurania Resources: Aurania berichtet, dass die ecuadorianische Regierung den Leiter von SENAGUA, die Wasserbehörde ersetzt hat
18:16 BUSINESS WIRE: ExaGrid kündigt neue Datenspeicherlösung für Acronis Cyber Backup an
17:37 BUSINESS WIRE: Tealium Expands Leadership Team, Appoints World-Class Marketing Executive as CMO
17:31 IRW-PRESS: IsoEnergy Ltd.: IsoEnergy erwirbt Collins Bay Erweiterung Uranvorkommen
17:18 IRW-PRESS: Sernova Corp. : Sernova bestätigt nachhaltiges C-Peptid-Niveau im Blut des ersten Patienten in seiner klinischen Phase-I/II-Studie für Typ-1-Diabetes nach dem Fasten
17:17 BUSINESS WIRE: Sierra Metals meldet Produktionsergebnisse für das 3. Quartal 2019, einschließlich konsolidierter Rekordergebnisse bei Metalläquivalentproduktion für das Quartal
17:00 BUSINESS WIRE: Taulia präsentiert Tool zur Liquiditätsplanung der nächsten Generation auf der EuroFinance Copenhagen 2019
16:51 BUSINESS WIRE: Bertin Energy & Environment erforscht umweltfreundliche Energieversorgungslösungen für das weltweit größte Radioteleskop SKA
Anzeige
Anzeige